跳转至内容
Merck
CN
  • Role of adenosine receptor subtypes in methamphetamine reward and reinforcement.

Role of adenosine receptor subtypes in methamphetamine reward and reinforcement.

Neuropharmacology (2014-10-11)
Kevin A Kavanagh, Drew C Schreiner, Sophia C Levis, Casey E O'Neill, Ryan K Bachtell
摘要

The neurobiology of methamphetamine (MA) remains largely unknown despite its high abuse liability. The present series of studies explored the role of adenosine receptors on MA reward and reinforcement and identified alterations in the expression of adenosine receptors in dopamine terminal areas following MA administration in rats. We tested whether stimulating adenosine A1 or A2A receptor subtypes would influence MA-induced place preference or MA self-administration on fixed and progressive ratio schedules in male Sprague-Dawley rats. Stimulation of either adenosine A1 or A2A receptors significantly reduced the development of MA-induced place preference. Stimulating adenosine A1, but not A2A, receptors reduced MA self-administration responding. We next tested whether repeated experimenter-delivered MA administration would alter the expression of adenosine receptors in the striatal areas using immunoblotting. We observed no change in the expression of adenosine receptors. Lastly, rats were trained to self-administer MA or saline for 14 days and we detected changes in adenosine A1 and A2A receptor expression using immunoblotting. MA self-administration significantly increased adenosine A1 in the nucleus accumbens shell, caudate-putamen and prefrontal cortex. MA self-administration significantly decreased adenosine A2A receptor expression in the nucleus accumbens shell, but increased A2A receptor expression in the amygdala. These findings demonstrate that MA self-administration produces selective alterations in adenosine receptor expression in the nucleus accumbens shell and that stimulation of adenosine receptors reduces several behavioral indices of MA addiction. Together, these studies shed light onto the neurobiological alterations incurred through chronic MA use that may aid in the development of treatments for MA addiction.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
盐酸, ACS reagent, 37%
Sigma-Aldrich
盐酸, ACS reagent, 37%
Sigma-Aldrich
盐酸 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
盐酸, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
盐酸, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
盐酸, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., fuming, ≥37%, APHA: ≤10
Supelco
蔗糖, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
盐酸, 36.5-38.0%, BioReagent, Molecular Biology
Sigma-Aldrich
腺苷, ≥99%
Supelco
盐酸 溶液, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
蔗糖, ACS reagent
Sigma-Aldrich
氯化氢 溶液, 1.0 M in diethyl ether
Sigma-Aldrich
盐酸 溶液, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
蔗糖, puriss., meets analytical specification of Ph. Eur., BP, NF
Supelco
氯化氢 – 甲醇 溶液, ~1.25 m HCl (T), derivatization grade (GC derivatization), LiChropur
Sigma-Aldrich
腺苷, BioReagent, suitable for cell culture
Sigma-Aldrich
盐酸 溶液, 32 wt. % in H2O, FCC
Sigma-Aldrich
氯化氢 溶液, 1.0 M in acetic acid
Sigma-Aldrich
盐酸, puriss., 24.5-26.0%
Supelco
Hydrogen chloride – ethanol, ~1.25 M HCl, derivatization grade (GC derivatization), LiChropur
Sigma-Aldrich
腺苷
Supelco
氯化氢 – 2-丙醇 溶液, ~1.25 M HCl (T), derivatization grade (GC derivatization), LiChropur
Supelco
腺苷, Pharmaceutical Secondary Standard; Certified Reference Material
腺苷, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
蔗糖, 99% (GC), Vetec, reagent grade
Sigma-Aldrich
腺苷, Vetec, reagent grade, 98%